
Cumberland Pharmaceuticals CPIX
$ 4.02
-2.43%
Quarterly report 2025-Q3
added 11-07-2025
Cumberland Pharmaceuticals Total Non Current Liabilities 2011-2025 | CPIX
Annual Total Non Current Liabilities Cumberland Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 23.9 M | 29.3 M | 29.3 M | 11.6 M | 5.49 M | 2.69 M | 903 K | 776 K | 4.97 M | 6.08 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.3 M | 776 K | 11.5 M |
Total Non Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
10.7 M | $ 2.67 | 0.38 % | $ 1.39 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
681 M | $ 4.32 | -3.78 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
1.02 B | $ 12.31 | -0.97 % | $ 630 M | ||
|
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
134 M | $ 21.57 | -0.1 % | $ 2.05 B | ||
|
OrganiGram Holdings
OGI
|
107 M | $ 1.71 | -4.75 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
105 M | $ 5.21 | -1.33 % | $ 686 M | ||
|
Evolus
EOLS
|
102 M | $ 6.65 | -3.7 % | $ 412 M | ||
|
Harrow Health
HROW
|
19.8 M | $ 50.72 | 1.26 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
1.71 M | $ 1.29 | 0.39 % | $ 22.5 M | ||
|
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 3.66 | 0.83 % | $ 4.54 M | ||
|
Bausch Health Companies
BHC
|
26.5 B | $ 7.16 | -0.56 % | $ 2.61 B | ||
|
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | ||
|
Rockwell Medical
RMTI
|
11.6 M | $ 0.81 | -6.28 % | $ 18.9 M | ||
|
Pacira BioSciences
PCRX
|
368 M | $ 26.09 | -1.6 % | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
1.03 M | $ 1.73 | -0.29 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
6.38 K | - | - | $ 33.6 M | ||
|
Veru
VERU
|
6.71 M | $ 2.2 | -8.33 % | $ 297 M | ||
|
Perrigo Company plc
PRGO
|
4.28 B | $ 13.92 | 0.72 % | $ 1.91 B | ||
|
ProPhase Labs
PRPH
|
7.94 M | $ 0.45 | -14.06 % | $ 7.13 M | ||
|
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
2.49 M | $ 1.47 | -13.53 % | $ 6.34 M | ||
|
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.39 | -2.59 % | $ 132 M | ||
|
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
115 M | $ 9.6 | -3.42 % | $ 682 M | ||
|
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
21.2 M | $ 5.65 | -3.25 % | $ 231 M | ||
|
SCYNEXIS
SCYX
|
53.4 M | $ 0.62 | 6.44 % | $ 29.7 M | ||
|
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
570 M | $ 9.36 | -2.47 % | $ 5.78 B | ||
|
TherapeuticsMD
TXMD
|
246 M | $ 1.68 | -3.45 % | $ 17.5 M |